No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients

Blood Purif. 2006;24(5-6):439-44. doi: 10.1159/000095360. Epub 2006 Aug 25.

Abstract

Background: It has been suggested that hemodiafiltration (HDF) is more efficient than hemodialysis (HD) in lowering plasma levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), which is a strong and independent predictor of overall mortality in ESRD patients.

Methods/patients: Twenty ESRD patients (11 women) were studied during both a single online HDF session and a single HD session. In each patient, ADMA, L-arginine, SDMA, beta(2)-microglobulin and urea were measured at several time points.

Results: Although HDF was clearly superior to HD in decreasing plasma beta(2)-microglobulin, there was no difference in the elimination characteristics of ADMA. However, HDF but not HD eliminated the nitric oxide synthase substrate L-arginine, making HD superior in increasing the L-arginine/ADMA ratio.

Conclusion: Neither HD nor HDF sufficiently removes the putative uremic toxin ADMA. The clinical significance of HD better improving the L-arginine/ADMA ratio (parameter of NO production) as compared to HDF needs to be determined.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Arginine / analogs & derivatives*
  • Arginine / blood
  • Arginine / urine
  • Female
  • Hemodiafiltration*
  • Humans
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / mortality
  • Kidney Failure, Chronic / therapy
  • Kidney Failure, Chronic / urine
  • Male
  • Middle Aged
  • Nitric Oxide / blood
  • Nitric Oxide Synthase / antagonists & inhibitors
  • beta 2-Microglobulin / blood

Substances

  • beta 2-Microglobulin
  • Nitric Oxide
  • N,N-dimethylarginine
  • Arginine
  • Nitric Oxide Synthase